Document is current

Article History

Received: 21 January 2020

Accepted: 3 May 2020

First Online: 14 May 2020

Ethics approval and consent to participate

: This study was approved by the local ethics committee, according to institutional policies. All patients gave informed consent prior to treatment.

: Not applicable due to absence of any personal or individual data in the present publication.

: <b>G.R.S:</b> Grants and personal fees from Carl Zeiss Meditec, outside the submitted work.<b>V.P.:</b> Nothing to disclose.<b>F.W.:</b> Reports personal fees from Celgene GmbH, personal fees from Roche Pharma AG, personal fees from Eli Lilly and Company, personal fees from Ipsen Pharma GmbH, grants and other from Carl Zeiss Meditec AG, grants and other from Elekta AB, outside the submitted work; In addition, Dr. Wenz has a patent Carl Zeiss Meditec AG licensed.<b>Y.A.:</b> Reports personal fees from Carl-Zeiss Meditec, personal fees from Merck-Serono, non-financial support from Elekta, outside the submitted work.<b>E.S.:</b> Grants from Ministry for Science and Arts, during the conduct of the study; other from Zeiss Meditec, outside the submitted work.<b>F.A.G.:</b> reports other from Implacit GmbH, non-financial support from Oncare GmbH, grants and personal fees from NOXXON Pharma AG, grants and personal fees from CARL ZEISS MEDITEC AG, personal fees from Bristol-Myers Squibb, personal fees from Roche Pharma AG, personal fees from MSD Sharp and Dohme GmbH, personal fees from AstraZeneca GmbH, outside the submitted work; In addition, Dr. Giordano has a patent (US 62/435405) pending.